385 related articles for article (PubMed ID: 18550199)
1. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
[TBL] [Abstract][Full Text] [Related]
2. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
[TBL] [Abstract][Full Text] [Related]
3. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Umayahara Y; Kosugi K; Yamasaki Y
Atherosclerosis; 2009 May; 204(1):288-92. PubMed ID: 18926539
[TBL] [Abstract][Full Text] [Related]
4. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes.
Yamamoto M; Yamaguchi T; Yamauchi M; Sugimoto T
Diabetes Care; 2009 Dec; 32(12):2263-8. PubMed ID: 19752174
[TBL] [Abstract][Full Text] [Related]
5. Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children.
Saito R; Araki S; Yamamoto Y; Kusuhara K
J Pediatr Endocrinol Metab; 2017 Jan; 30(1):63-69. PubMed ID: 27941172
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.
Kerkeni M; Saïdi A; Bouzidi H; Ben Yahya S; Hammami M
Microvasc Res; 2012 Nov; 84(3):378-83. PubMed ID: 22835520
[TBL] [Abstract][Full Text] [Related]
8. Association between endogenous secretory receptor for advanced glycation-end products (esRAGE) and carotid intima-media thickness in type 2 diabetes.
Lin X; Chen X; Ye J; Li Q; Zhou J; Wu X; Huang Y; Li X; Shi Y; Li S; Li L; Cai H
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):277-80. PubMed ID: 24839222
[TBL] [Abstract][Full Text] [Related]
9. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Nakatani Y; Ohtoshi K; Hayaishi-Okano R; Kosugi K; Hori M; Yamasaki Y
Diabetes Care; 2005 Nov; 28(11):2716-21. PubMed ID: 16249545
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
11. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis.
Koyama H; Shoji T; Yokoyama H; Motoyama K; Mori K; Fukumoto S; Emoto M; Shoji T; Tamei H; Matsuki H; Sakurai S; Yamamoto Y; Yonekura H; Watanabe T; Yamamoto H; Nishizawa Y
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2587-93. PubMed ID: 16224056
[TBL] [Abstract][Full Text] [Related]
12. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
[TBL] [Abstract][Full Text] [Related]
13. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
14. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Yamasaki Y
Diab Vasc Dis Res; 2008 Sep; 5(3):190-7. PubMed ID: 18777492
[TBL] [Abstract][Full Text] [Related]
15. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.
Tan KCB; Chow WS; Tso AWK; Xu A; Tse HF; Hoo RLC; Betteridge DJ; Lam KSL
Diabetologia; 2007 Sep; 50(9):1819-1825. PubMed ID: 17639302
[TBL] [Abstract][Full Text] [Related]
17. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography.
Yang SJ; Kim S; Hwang SY; Kim TN; Choi HY; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
Atherosclerosis; 2012 Feb; 220(2):402-6. PubMed ID: 22137663
[TBL] [Abstract][Full Text] [Related]
18. Severity of diabetic microvascular complications is associated with a low soluble RAGE level.
Grossin N; Wautier MP; Meas T; Guillausseau PJ; Massin P; Wautier JL
Diabetes Metab; 2008 Sep; 34(4 Pt 1):392-5. PubMed ID: 18701333
[TBL] [Abstract][Full Text] [Related]
19. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes.
Yoshida N; Okumura K; Aso Y
Metabolism; 2005 Mar; 54(3):345-50. PubMed ID: 15736112
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
